These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119 [TBL] [Abstract][Full Text] [Related]
14. Waldenstrom's macroglobulinemia in the era of immunotherapy. Vaxman I; Gertz M Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730 [TBL] [Abstract][Full Text] [Related]
16. Waldenström's macroglobulinemia: a review of therapy. Gertz MA Leuk Lymphoma; 2002 Aug; 43(8):1517-26. PubMed ID: 12400593 [TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of Waldenström's macroglobulinemia. Johnson SA Expert Rev Anticancer Ther; 2006 Mar; 6(3):329-34. PubMed ID: 16503850 [TBL] [Abstract][Full Text] [Related]
18. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121 [TBL] [Abstract][Full Text] [Related]